1. 2021. Fereshetyan K. Chavushyan V., Danielyan M., Yenkoyan K. Assessment of behavioral, morphological and electrophysiological changes in prenatal and postnatal valproate induced rat models of autism spectrum disorders. Sientific reports. 11:23471, doi.org/10.1038/s41598-021-02994-6.
2. 2021. Harutyunyan A, Urlesberger B, Muradyan A, Hovhannisyan M, Badalyan A, Kalenteryan H, Haxhija E, Sargsyan K, Yenkoyan K, Babloyan A. Introducing multi-modal enteral medication reduced morbidity and mortality associated with necrotising enterocolitis. Acta Paediatr.110(2):458-464. doi:10.1111/apa.15466.
3. 2021. Melkonyan M, Manukyan A, Hunanyan L, Grigoryan A, Harutyunyan H, Sukiasyan L, Danielyan L, Yenkoyan K.Alpha2- drenoblockers Regulate Development of Oxidative Stress and Cognitive Behaviour of Rats under Chronic Acoustic Stress Conditions. harmaceuticals (Basel). 2;14(6):529. doi:10.3390/ph14060529.
4. 2021. Aghajanov M, Matinyan S, Chavushyan V, Danielyan M, Karapetyan G, Mirumyan M, Fereshetyan K, Harutyunyan H, Yenkoyan K. The Involvement of Insulin-Like Growth Factor 1 and Nerve Growth Factor in Alzheimer's Disease-Like Pathology and Survival Role of the Mix of Embryonic Proteoglycans: Electrophysiological Fingerprint, Structural Changes and Regulatory Effects on Neurotrophins. Int J Mol Sci. 30;22(13):7084. doi: 10.3390/ijms22137084.
5. 2020. Vergine Chavushyan, Ani Soghomonyan, Gohar Karapetyan, Karen Simonyan, Konstantin Yenkoyan “Disruption of Cholinergic Circuits as an Area for Targeted Drug Treatment of Alzheimer’s Disease: In Vivo Assessment of Short-Term Plasticity in Rat Brain”. Pharmaceuticals, 2020, 13(10), 297; doi: 10.3390/ph13100297.
6. 2020. Chavushyan V., Matinyan S., Danielyan M., Aghajanov M., Yenkoyan K. “Embryonic proteoglycans regulate monoamines in the rat frontal cortex and hippocampus in Alzheimer's disease-like pathology”. Neurochemistry International, 2020 Aug 25;140:104838. doi: 10.1016/j.neuint.2020.104838.
7. 2020. Ute A. Schwinghammer, Magda M. Melkonyan, Lilit Hunanyan, Roman Tremmel, Ralf Weiskirchen, Erawan Borkham-Kamphorst, Elke Schaeffeler, Torgom Seferyan, Wolfgang Mikulits, Konstantin Yenkoyan, Matthias Schwab, Lusine Danielyan “α2-Adrenergic Receptor in Liver Fibrosis: Implications for the Adrenoblocker Mesedin”. Cells, 2020 9(2), 456.
8. 2019. Aghajanov M., Chavushyan V., Matinyan S., Danielyan M., Yenkoyan K. “Alzheimer's disease-like pathology-triggered oxidative stress, alterations in monoamines levels, and structural damage of locus coeruleus neurons are partially recovered by a mix of proteoglycans of embryonic genesis”. Neurochemistry International. 2019 16; 131:104531
9. 2019. Drews H.J., Yenkoyan K., Lourhmati A., Buadze M., Kabisch D., Verleysdonk S., Petschak S., Beer-Hammer S., Davtyan T., Frey W.H. 2nd, Gleiter C.H., Schwab M., Danielyan L. “Intranasal losartan decreases perivascular beta amyloid, inflammation and the decline of neurogenesis in hypertensive rats”. Neurotherapeutics, 2019 16(3):725-740.
10. 2018. Yenkoyan K., Harutyunyan H., Harutyunyan A. “A certain role of SOD/CAT imbalance in pathogenesis of autism spectrum disorders.” Free Radic Biol Med., 123:85-95.
11. 2018. Yenkoyan K., Fereshetyan K., Matinyan S., Chavushyan V., Aghajanov M. “The role of monoamines in the development of Alzheimer's disease and neuroprotective effect of a proline rich polypeptide.” Prog Neuropsychopharmacol Biol Psychiatry., 86:76-82.
12. 2017. Melkonyan M., Hunanyan L., Lourhmati A., Layer N., Beer-Hammer S., Yenkoyan K., Schwab M., Danielyan L. “Neuroprotective, neurogenic, and amyloid beta reducing effect of a novel alpha 2-adrenoblocker, mesedin, on astroglia and neuronal progenitors upon hypoxia and glutamate exposure”. Int J Mol Sci. 2017, 19(1).
13. 2017. K. Yenkoyan, Grigoryan A, Fereshetyan K, Yepremyan D. “Advances in understanding the pathophysiology of autism spectrum disorders” Behav Brain Res. V. 31, p. 92-101.